Skip to content
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Day: September 3, 2024

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More
Page1 Page2 Page3
RECENT POSTS

Democratic Republic of the Congo Faces New Ebola Challenge as Schools Reopen

August 31, 2026

The Devastating Impact of Copper and Cobalt Mining Pollution in Lualaba, DRC

August 29, 2026

UN Chief Calls for Urgent Action as Ebola Cases Surge in DR Congo

August 27, 2026

African Bundibugyo Ebolavirus Vaccine Candidate to Be Advanced to Clinical Trials

August 27, 2026

Ebola Outbreak Over in Uganda but Cases Still Rising in DR Congo

August 27, 2026

100 Days of Ebola: Unprecedented Outbreak in DRC Demands Urgent Action

August 24, 2026

Democratic Republic of the Congo Marks 100 Days of Fastest Growing Ebola Outbreak

August 24, 2026

DR Congo and AFC/M23 Group Concur on Peace Negotiation Roadmap Following Swiss Talks

August 23, 2026
Copyright © 2026 Le Congo Tribune. All Rights Reserved.